ArticleJournal of microbiology and biotechnology2025
Effect of Particulate Matter in Atopic Dermatitis through HDACs and Filaggrin Alteration.
Article in Journal of microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Skin Barrier-Improving and Anti-Inflammatory Effects of Exosomes Derived from theJournal of microbiology and biotechnology · 2026Article
- Histones deacetylases in the epidermis: structure, functions and therapeutic implications.Frontiers in epigenetics and epigenomics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atopic dermatitis (AD) is a skin condition that can be exacerbated by particulate matter (PM). The primary causes of AD are believed to be impairments in the skin barrier, such as filaggrin (FLG) abnormalities. Although there is substantial evidence for genetic factors contributing to AD, it is challenging to attribute the disease's predisposition solely to genetics. We hypothesize that PM may induce epigenetic modifications in AD, impacting FLG expression. Here, we assessed histone deacetylases (HDACs) and FLG levels under AD conditions with or without exposure to PM using qRT-PCR, western blotting, and immunofluorescence. Additionally, we observed changes in these molecules when co-treated with the HDAC inhibitor, trichostatin A (TSA). FLG levels tended to decrease when PM or IL-4/13 were given individually, and a further decrease upon IL-4/13 and PM cotreatment. Interestingly, HDAC3 and HDAC6 are increased when they were both given PM10 and IL-4/13 co-treatment compared to IL-4/13 treatment alone. FLG levels exhibited a significant restoration and the levels of HDACs were changed when treated with TSA than with IL-4/13 or IL-4/13+PM co-treatment. We found changes in FLG and HDACs in the AD-like in vivo model and in this model with PM. Our findings suggest that PM can induce epigenetic alterations in AD. Treatment with TSA ameliorates these effects on FLG expression, indicating its potential as a novel therapeutic approach for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.